{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-111405","form_type":"8-K","ticker":"PRGO","cik":"0001585364","company_name":"PERRIGO Co plc","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.092997+00:00","generated_at":"2026-06-03T07:58:37.176251+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Perrigo to sell HRA Pharma Rare Diseases to Esteve for up to €275M","bullets":["Total consideration up to €275M: €190M cash plus up to €85M earnout on sales milestones.","Esteve Healthcare signed binding offer; Perrigo has a put option to finalize sale.","Transaction expected to close in Q3 2024, subject to Works Council consultation and regulatory approvals.","Sale includes HRA Pharma Rare Diseases business; Perrigo will proceed after French Works Council process."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-111405","json":"https://secwatch.observer/filing/0001193125-24-111405.json","markdown":"https://secwatch.observer/filing/0001193125-24-111405.md","text":"https://secwatch.observer/filing/0001193125-24-111405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585364/000119312524111405/0001193125-24-111405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585364/000119312524111405/d813932d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:58:37.176251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}